2023年1月18日 · The spotlight remained on Nvidia, whose chips are powering much of the move into AI and whose stock has become a symbol of the surrounding frenzy.

2020年7月13日 · Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

2023年5月11日 · Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the …

2023年1月5日 · Under the terms of the license agreement, Bellerophon will receive a license payment of $6 million, payable within 90 days subject to certain closing conditions set forth in …

2021年5月26日 · “I am pleased to continue my support of Bellerophon in my new role as Chairman,” said Dr. Amin. “Bellerophon is a highly innovative company and its INOpulse …

2023年4月3日 · Consensus from 2 of the American Biotechs analysts is that Bellerophon Therapeutics is on the verge of breakeven. They expect the company to post a final loss in …

2023年6月5日 · Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

2023年6月6日 · Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

2020年5月11日 · Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19

2022年9月28日 · Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. …